hospitals in Jiangxi Province. Patients were divided into 4 groups according to the age and causative agent: young patients (15-64 years) with viral pneumonia (group 1) or bacterial pneumonia (group 2), and elderly patients (over 65 years) with viral pneumonia (group 3) or bacterial pneumonia (group 4). Cure rate, improvement rate, uncured rate, death rate, average hospitalization days and total hospitalization costs were compared between patients treated with Xiyanping injection and those treated with conventional treatment. Results: 114 patients treated with Xiyanping injection (60, 21, 18 and 15 patients in group 1-4, respectively) and 3,107 patients with conventional treatment (893, 376, 1,322 and 516 patients in group 1-4, respectively) were included. After prosperity score matching, no significant differences in the cure rate, improvement rate, uncured rate, and death rate when comparing patients treated with Xiyanping injection and those treated with conventional treatment. Patients treated with Xiyanping injection had significantly shorter hospital stay for Group 1 patients (5.14262.54 vs. 6.9863.86 days), Group 2 patients (5.0062.61 vs. 7.9263.75 days) and Group 4 patients (5.5862.97 vs. 9.2563.19 days). The total cost of hospitalization was lower for patients treated with Xiyanping injection than those treated with conventional treatment in Group 1, 2 and 4 although there were no significant statistics differences. Conclusions: Comparing with conventional treatment, Xiyanping injection provided the same clinical outcome but with shorter hospital stay resulting in reduced hospitalization cost for adults with community acquired pneumonia in China.
to the institution and a percentage change from revenue of -514,0%. ConClusions: We verified that the reimbursement value from) the health system was insufficient to cover the costs of the infusion procedures, significantly compromising the hospital budget for patients treated with immunobiological (immunobiologics ou immunobiological agents/drugs).
Central, and West South Central regions, respectively. ConClusions: The cost and payment of treating an opioid related visit were highest in West South Central region and West North Central, respectively. The costs associated with the visit were typically higher than the average payment. Opioid-related visits are a highly prevalent and costly epidemic placing a large burden on US hospitals.
Conclusions: This study demonstrate that biosimilar drug market increased during the period. The "Health National Strategy » biosimilar objective for 2022: 80% of market share is achievable if the market keeps the actual trend. Patient's characteristics description could be complementary to this study, to give more information to the biosimilar landscape.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.